Access to Provincial Drug Cost Reimbursement for MS Therapies
Once a new therapy is approved by the Health Products and Food Branch of Health Canada and assessed by the Common Drug Review, the Ontario government's own team of clinical experts and two lay citizens, the Committee to Evaluate Drugs (CED), determines whether it should be listed as a benefit under Ontario's drug plans. Usually drugs have to be listed on the provincial formulary to be covered, however, a special process — called Exceptional Access or “Section 16” — provides coverage for drugs that have not been listed as a benefit on the provincial formulary, but have been approved by Health Canada and reviewed by the CED.
 The disease modifying therapies for multiple sclerosis fall into the Exceptional Access program. Avonex™ (interferon beta-1a), Betaseron® (interferon beta-1b), Copaxone™ (glatiramer acetate) and Rebif® (interferon beta-1a) may be accessed by people who need assistance with the cost of the drugs through Exceptional Access. These individuals must apply and be approved before they are eligible to receive assistance through Ontario's drug cost reimbursement programs. Approval is granted on an individual’s ability to meet certain clinical criteria established by the CED.
In addition to the disease modifying therapies, some symptom management therapies may be obtained through the Exceptional Access program, while others – often older therapies – are listed on the provincial drug formulary. In some instances, these older drugs have remained as first line therapies. The symptom management drugs that may be obtained through the Exceptional Access program include, but may not be limited to:
Symptom Management chart
Symptom Management |
Brand Name Medication |
Fatigue |
Alertec® (modafinil)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, reimbursement for Alertec® will be provided for the symptomatic relief of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. |
Neuropathic pain |
Lyrica® (pregablin)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, requests for Lyrica® are considered for patients with neuropathic pain who have failed an adequate trial of a tricyclic antidepressant and of gabapentin, unless otherwise contraindicated. Objective evidence of a neuropathic cause of pain (e.g., as shown by relevant tests, such as electrodiagnostic testing and/or findings from a physical examination by a specialist to support the diagnosis of neuropathic pain) is required.
Multiple sclerosis-related pain is accepted as neuropathic pain.
|
Neuropathic pain |
Neurontin® (gabapentin)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, requests for Neurontin® are considered for patients with neuropathic pain who have failed an adequate trial of a tricyclic antidepressant. Objective evidence of a neuropathic cause of pain (e.g., as shown by relevant tests, such as electrodiagnostic testing and/or findings from a physical examination by a specialist to support the diagnosis of neuropathic pain) is required.
Multiple sclerosis-related pain is accepted as neuropathic pain.
|
Neuropathic pain |
Sativex® (Cannabis sativa L. extract)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, requests for Sativex® will be considered for MS-related neuropathic pain in those patients who have failed an adequate trial or who have intolerable side effects or contraindications (e.g. inability to swallow) to the formulary cannabinoid alternatives. In addition, given the longer clinical experience with tricyclic antidepressants, gabapentin and pregabalin, requests for Sativex will be considered for patients with MS-related neuropathic pain who have failed adequate trials of a tricyclic antidepressant and gabapentin and pregabalin. |
Neuropathic pain |
Topamax® (topiramate)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, Topamax® is reviewed on a case by case basis for patients who have tried an adequate trial of a tricyclic antidepressant, gabapentin and lamotrigine. |
Spasticity |
Intrathecal Baclofen (ITB Therapy) (baclofen injectable)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, Intrathecal Baclofen is reviewed on a case by case basis. |
Spasticity |
Zanaflex® (tizanidine)
According to Ontario’s Ministry of Health and Long-Term Care guidelines, under the Exceptional Access Program, Zanaflex® is considered for the treatment of spasticity in patients who have failed and/or cannot tolerate at least two other available alternatives, including baclofen, diazepam or dantrolene. |
The following information provides additional details about the criteria for access and reimbursement process in Ontario for the MS therapies. Individuals who need assistance with the request process can contact the MS Society for support.
Common questions and answers
When can I apply for reimbursement?
You will be eligible for reimbursement under Ontario's
drug programs once
your Exceptional Access request is approved.
back to top
How do I apply for Exceptional Access?
Your doctor must submit a standard Exceptional Access
request form on your
behalf, describing your medication requirements to the Ministry
of Health and Long-Term Care Drug Programs Branch. Medical
experts will review your doctor's request and will advise
him or her, within two to three weeks, whether coverage has
been
approved.
The Exceptional Access request form can also be accessed on
the Ontario
Public Drug Program’s website.
back to top
What can I do if my Exceptional Access request is denied?
Your doctor can appeal the rejection by writing the Ministry
of Health and Long-Term Care Drug Programs Branch. Most rejections
occur because the physician initially provided inadequate
information. You may want to review the eligibility criteria
outlined below
with your physician.
back to top
What are the Exceptional Access criteria?
Generally, to be approved, people starting treatment must meet
the criteria that were used in the clinical trials:
-
Patient can be assessed by GP or specialist
-
Prescription
must be approved by Ministry of Health and Long-Term Care panel
(Exceptional Access)
-
Approval is given for up to one year
For disease modifying therapies, people must also meet the following
requirements:
-
Patient must have clinically definite MS (at least
2 attacks in past 2 years) and ambulatory with or without
mobility aids:
Avonex® (EDSS 3.5 or less)
Betaseron® (EDSS 6.0 or less)
Copaxone® (EDSS 5.0 or less)
and Rebif® (EDSS 6.0 or less)
-
The Ontario Drug Benefit Program will approve an initial treatment period of 6 months for patients requiring the administration of Tysabri® for the treatment of Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis (RES-RRMS) who meet specific criteria. For more information on these criteria please contact your physician or the Exceptional Access Program at Ontario Public Drug Programs 1-866-598-6530 or 416-327-8109.
- For people who have a high risk of developing MS (Clinically
Isolated Syndrome or CIS), two therapies - Avonex® and Betaseron® -
may be approved under the Exceptional Access program. To
gain Exceptional Access, individuals must have one acute
attack
and brain lesions typical of MS.
Criteria for symptom management treatments vary. Some information regarding criteria is provided above. Please consult your physician for additional information.
back to top
What are the criteria for people already on treatment?
People who are on active treatment probably will have had fewer
attacks and may be concerned about meeting the above criteria
when applying to continue on therapy. In this case, your
physician should explicitly state that the request is for continuation
of therapy. He or she should provide detailed information
about
your diagnosis, disability score and frequency of attacks
before you started on therapy on the standard
Exceptional Access request form. This form
can also be accessed on the Ontario
Public Drug Program’s
website.
In addition, your physician should provide information about
your clinical status while on treatment including details about
any attacks or side effects you have experienced while on the
therapy as well as your current Expanded Disability Status Scale
(EDSS) score.
Will my Exceptional Access need to be renewed periodically?
Yes. Exceptional Access is given on a case-by-case basis for periods of time usually ranging from six to 12 months. In 2008, Ontario Public Drug Programs introduced a Telephone Request System (TRS) through which renewals of Avonex®, Betaseron®, Copaxone® and Rebif® may be granted. It is recommended that you discuss this renewal option with your physician six to eight weeks before the expiry of your Exceptional Access approval.
For medications not eligible for renewal through the Telephone Request System, six weeks before the expiry of the approval, your physician must re-submit a standard
Exceptional Access request form to Ontario Public Drug Programs. You should remind your physician to do this. See above for information about the criteria for people already on treatment.
The Exceptional Access request form can also be accessed on the Ontario Public Drug Program’s website.
back to top
What are the criteria for renewals?
To have your Exceptional Access renewed, you must:
-
Be ambulatory, in the case of disease modifying
therapies (see above);
-
Have experienced no deterioration in
your medical condition while on treatment.
back to top
Where can I get help to pay for the drug?
Once Exceptional Access is granted, individuals can access either
the Ontario Drug Benefits Plan or the Trillium Drug Program to
help cover the cost of the drug.
Ontario Drug Benefits Plan
Social assistance (Ontario Works) and Ontario Disability Support
Plan recipients are covered under this plan and pay only $2
per prescription.
Trillium Drug Program
People who are not 100% covered by a private or employer paid
drug plan or who have no drug program can apply to the Trillium
Drug Program (TDP) to help pay for a large portion of the cost
of the drug. Requests forms and guides are available from your
local pharmacy.
back to top
Can I apply to Trillium if I have private drug coverage?
Yes. You can use the Trillium Drug Program (TDP) to help pay
the difference between the cost of some drugs and what your private
benefits cover. Remember you will need Exceptional Access approval
to be reimbursed under the Trillium program for those drugs not
listed on the Ontario Public Drug Programs Formulary.
back to top
Should I wait to purchase the drug until my Exceptional Access
request is approved?
Yes, because you will not be reimbursed for the cost until your
Exceptional Access request is approved. However, individuals
applying to the Trillium Drug Program (TDP) for the first time
should be aware that requests can take up to two weeks to process.
It is advisable to submit your request to the TDP at the same
time as the Exceptional Access request.
back to top
How will I know my Exceptional Access request has been approved?
Check with your physician because Ontario Public Drug Programs
will notify him or her about whether coverage has been approved
for you. Most decisions are made within two to six weeks.
back to top
How will I know my request to Trillium Drug Program has been
processed?
Once your request is processed, you will receive a letter from
Trillium Drug Program advising that you are enrolled in the program.
You may also check with your pharmacist or contact the Trillium
Drug Program directly about the status of your request (please
see the end of this section for contact information). It will
take approximately two weeks for the Trillium Drug Program to
process your request.
back to top
Do I have to pay a portion of the cost myself?
Under the Trillium program you must pay a certain amount on
prescription drugs (deductible) each year. Usually it is about
4% of net family income.
back to top
Do I have to pay my deductible all at once?
No. The deductible can be paid in quarterly installments over
the Trillium Drug Program year (August 1 to July 31). Once the
deductible has been paid in each quarter, your family will receive
full drug benefits for that quarter.
back to top
Do I have to pay the full deductible if I apply later in the
year?
No. Your deductible will be based only on the number of months
left in the Trillium Drug Program year. Your enrollment date
will be used to calculate your prorated quarterly deductible.
Your family will receive full drug benefits, once the deductible
is paid in each quarter.
back to top
Do I have to reapply every year?
Yes. Once registered with the Trillium program, you will be
sent a pre-completed form at the end of each fiscal year. If
the information contained in the form is correct, you should
simply sign and return the form to the program. However, if your
income and/or family status have changed, you must notify the
program at this time, as this will affect your deductible.
Useful contact information
Exceptional Access Program
Ontario Public Drug Programs at 1-866-598-6530 or 416-327-8109
or discuss with your physician. You may also visit www.health.gov.on.ca/english/providers/program/
drugs/funded_drug/fund_odbp.html.
back to top
Trillium Drug Program
Ministry of Health at 1-800-575-5386 or 416-642-3038 or contact
your local pharmacy. Information about the Trillium Drug
Program, including forms and guides, is available at www.health.gov.on.ca/english/providers/program/
drugs/funded_drug/fund_trillium.html.
back to top
Ontario Drug Benefits Plan
Ministry of Health and Long-Term Care Drug Programs Branch
at 1-866-598-6530 or 416-327-8109. Additional information on
the
Ontario Drug Benefits Plan can be found at www.health.gov.on.ca/english/providers/program/
drugs/funded_drug/fund_odbp.html.
back to top
Assistance with the request process
The Client Information & Referral Coordinator can help clients
with general information about these application processes. Contact
1-800-268-7582 ext. 3133.
back to top
|